Puma Biotechnology (NASDAQ:PBYI) Hits New 12-Month High – Should You Buy?

Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) hit a new 52-week high during trading on Wednesday . The company traded as high as $9.73 and last traded at $9.70, with a volume of 224766 shares trading hands. The stock had previously closed at $9.35.

More Puma Biotechnology News

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Zacks raised its fiscal 2026 EPS forecast to $0.37 from $0.31, above the current full-year consensus of $0.31. It also increased its fiscal 2028 estimate to $0.45 from $0.42, signaling improved expectations for near- and longer-term profitability.
• Positive Sentiment: Quarterly estimates for the first and second quarters of 2027 were lifted to $0.04 and $0.07, respectively, from $0.03 and $0.06.
• Neutral Sentiment: The current full-year consensus EPS estimate remains at $0.31, indicating that the revisions have not yet changed the broader market outlook for the company’s current fiscal year.
• Negative Sentiment: Zacks cut its fiscal 2027 EPS forecast to $0.14 from $0.18. It also lowered fourth-quarter 2027 EPS to $0.02 from $0.04 and third-quarter 2027 EPS to $0.02 from $0.05.
• Negative Sentiment: The third-quarter 2026 EPS estimate was reduced to $0.06 from $0.08, suggesting softer near-term earnings expectations.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Wall Street Zen upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Weiss Ratings raised shares of Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. Finally, TD Cowen raised their target price on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a research note on Friday, August 7th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.00.

Puma Biotechnology Trading Down 2.9%

The business’s 50 day moving average price is $8.50 and its 200-day moving average price is $7.51. The company has a market cap of $485.74 million, a price-to-earnings ratio of 18.10 and a beta of 1.24.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.15. The business had revenue of $56.50 million for the quarter, compared to analyst estimates of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%. Equities research analysts forecast that Puma Biotechnology, Inc. will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Alan Auerbach sold 44,058 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $8.26, for a total value of $363,919.08. Following the transaction, the chief executive officer owned 7,261,671 shares of the company’s stock, valued at approximately $59,981,402.46. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jay Moyes sold 22,000 shares of Puma Biotechnology stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $7.22, for a total value of $158,840.00. Following the sale, the director directly owned 58,322 shares of the company’s stock, valued at approximately $421,084.84. The trade was a 27.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 132,028 shares of company stock valued at $1,006,711 in the last ninety days. 22.20% of the stock is currently owned by company insiders.

Institutional Trading of Puma Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of PBYI. Royal Bank of Canada grew its position in shares of Puma Biotechnology by 244.5% during the 1st quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 3,066 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Puma Biotechnology in the second quarter valued at approximately $35,000. Cerity Partners LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at approximately $36,000. California State Teachers Retirement System boosted its stake in shares of Puma Biotechnology by 110.2% in the second quarter. California State Teachers Retirement System now owns 4,898 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 2,568 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Puma Biotechnology by 39.7% in the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 2,290 shares during the period. Institutional investors and hedge funds own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a late?stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small?molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early?stage HER2-positive breast cancer.